Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELAN Stock Forecast 2026-2027
$25.83
Current Price
$12.76B
Market Cap
Buy 16
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ELAN Price Targets
+23.9%
To High Target of $32.00
+16.1%
To Median Target of $30.00
-11.0%
To Low Target of $23.00
ELAN Price Momentum
+4.1%
1 Week Change
+6.6%
1 Month Change
+74.8%
1 Year Change
+14.1%
Year-to-Date Change
-6.8%
From 52W High of $27.72
+92.9%
From 52W Low of $13.39
📊 TOP ANALYST CALLS
Did ELAN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Elanco is one of their latest high-conviction picks.
Latest ELAN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ELAN has a bullish consensus with a median price target of $30.00 (ranging from $23.00 to $32.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $25.83, the median forecast implies a 16.1% upside. This outlook is supported by 16 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Steve Scala at TD Cowen, projecting a 23.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELAN Analyst Ratings
16
Buy
1
Hold
0
Sell
ELAN Price Target Range
Low
$23.00
Average
$30.00
High
$32.00
Current: $25.83
Latest ELAN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELAN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 18, 2026 | TD Cowen | Steve Scala | Buy | Maintains | $32.00 |
| May 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 7, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Apr 15, 2026 | Citigroup | Buy | Initiates | $N/A | |
| Feb 25, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 25, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Feb 24, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Feb 19, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Jan 22, 2026 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Dec 18, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Nov 21, 2025 | Keybanc | Overweight | Initiates | $N/A | |
| Nov 6, 2025 | UBS | Buy | Maintains | $N/A | |
| Oct 20, 2025 | UBS | Buy | Maintains | $N/A | |
| Oct 7, 2025 | JP Morgan | Overweight | Upgrade | $N/A | |
| Sep 24, 2025 | Stifel | Buy | Maintains | $N/A | |
| Aug 11, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Aug 8, 2025 | UBS | Buy | Maintains | $N/A | |
| Jul 23, 2025 | UBS | Buy | Maintains | $N/A | |
| Jul 17, 2025 | Leerink Partners | Outperform | Upgrade | $N/A |
Elanco Animal Health Incorporated (ELAN) Competitors
The following stocks are similar to Elanco based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elanco Animal Health Incorporated (ELAN) Financial Data
Elanco Animal Health Incorporated has a market capitalization of $12.76B with a P/E ratio of 377.1x. The company generates $4.89B in trailing twelve-month revenue with a -4.9% profit margin.
Revenue growth is +14.9% quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of -3.8%.
Valuation Metrics
Market Cap
$12.76B
Enterprise Value
$16.43B
P/E Ratio
377.1x
PEG Ratio
-17.6x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+14.9%
Gross Margin
+57.3%
Operating Margin
+12.3%
Net Margin
-4.9%
EPS Growth
-14.9%
Financial Health
Cash/Price Ratio
+3.3%
Current Ratio
2.2x
Debt/Equity
66.2x
ROE
-3.8%
ROA
+1.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Elanco Animal Health Incorporated (ELAN) Business Model
About Elanco Animal Health Incorporated
What They Do
Develops innovative products for animal health.
Business Model
Elanco operates a pharmaceutical business model, generating revenue by offering a diverse portfolio of products aimed at preventing and treating diseases in both companion animals and livestock. The company serves veterinarians, farmers, and pet owners, capitalizing on its extensive research-driven expertise and international presence in over 90 countries.
Additional Information
Founded in 1954, Elanco has a strong heritage in animal health, earning more than half of its revenue from international markets. The company's commitment to research and sustainable practices makes it a key player in enhancing animal welfare, supporting food security, and advancing the global animal health industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9,400
CEO
Mr. Jeffrey N. Simmons
Country
United States
IPO Year
2018
Website
www.elanco.comElanco Animal Health Incorporated (ELAN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jul 15, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Elanco Animal Health (ELAN) has a strong earnings surprise history and favorable conditions for a potential earnings beat in its upcoming quarterly report.
Why It Matters
Elanco's strong earnings surprise history and favorable conditions suggest potential for a positive earnings report, indicating possible stock price appreciation and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
9 days ago
Quick Summary
Elanco Animal Health (NYSE: ELAN) will release its Q2 2026 financial results on August 5, 2026, followed by a conference call for investors and media.
Why It Matters
Elanco's upcoming Q2 2026 financial results and conference call could influence stock performance, providing insights into growth, profitability, and market positioning.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors should monitor ELAN stock due to recent activity in the options market, indicating potential volatility or trading interest.
Why It Matters
ELAN stock movements in the options market may indicate shifts in investor sentiment or expectations, impacting stock price volatility and potential trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Elanco Animal Health (NYSE: ELAN) plans to launch Elanco Ventures, a $25 million corporate venture capital platform to invest in innovations in animal health, focusing on therapeutics and technologies.
Why It Matters
Elanco's new $25 million venture platform signals a strategic shift towards innovation in animal health, potentially enhancing growth and market position, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Elanco Animal Health received USDA approval for TruCan Ultra Lyme-L4, a 1/2 mL combination vaccine for dogs against Lyme disease and leptospirosis. Shipping expected in 30 days.
Why It Matters
Elanco's approval of TruCan Ultra Lyme-L4 enhances its vaccine portfolio, potentially increasing market share and revenue, while addressing pet health concerns, impacting investor sentiment positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Jeffrey Simmons of Elanco discusses the development of a vaccine for the New World Screwworm infection in U.S. cattle on 'Closing Bell Overtime.'
Why It Matters
Advancements in agricultural biotech, like a cattle vaccine, can boost Elanco's market position and revenue potential, influencing investor sentiment and stock performance.
Source: CNBC Television
Market Sentiment:
Positive
Frequently Asked Questions About ELAN Stock
What is Elanco Animal Health Incorporated's (ELAN) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Elanco Animal Health Incorporated (ELAN) has a median price target of $30.00. The highest price target is $32.00 and the lowest is $23.00.
Is ELAN stock a good investment in 2027?
According to current analyst ratings, ELAN has 16 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $25.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELAN stock?
Wall Street analysts predict ELAN stock could reach $30.00 in the next 12 months. This represents a 16.1% increase from the current price of $25.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elanco Animal Health Incorporated's business model?
Elanco operates a pharmaceutical business model, generating revenue by offering a diverse portfolio of products aimed at preventing and treating diseases in both companion animals and livestock. The company serves veterinarians, farmers, and pet owners, capitalizing on its extensive research-driven expertise and international presence in over 90 countries.
What is the highest forecasted price for ELAN Elanco Animal Health Incorporated?
The highest price target for ELAN is $32.00 from Steve Scala at TD Cowen, which represents a 23.9% increase from the current price of $25.83.
What is the lowest forecasted price for ELAN Elanco Animal Health Incorporated?
The lowest price target for ELAN is $23.00 from at , which represents a -11.0% decrease from the current price of $25.83.
What is the overall ELAN consensus from analysts for Elanco Animal Health Incorporated?
The overall analyst consensus for ELAN is bullish. Out of 2 Wall Street analysts, 16 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are ELAN stock price projections?
Stock price projections, including those for Elanco Animal Health Incorporated, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:22 AM UTC